ArticleBJU international2012
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.
Article in BJU international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort.Frontiers in oncology · 2018Article
- Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.Urology practice · 2017Article
- Prostate cancer screening with prostate-specific antigen: A guide to the guidelines.Prostate international · 2016Review
- Overdiagnosis and overtreatment of prostate cancer.European urology · 2014Review
- Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy.Prostate international · 2014Article
- Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.The Journal of urology · 2014Article
- Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.Reviews in urology · 2014Review
- Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.International journal of clinical and experimental pathology · 2014Article
- Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2013Article
- PSA Velocity in Risk Stratification of Prostate Cancer.Reviews in urology · 2013Review
- Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA.Reviews in urology · 2010Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
objective• To determine whether the prostate-specific antigen velocity (PSAV) risk count (i.e. the number of times PSAV exceeds a specific threshold) could increase the specificity of screening for prostate cancer and potentially life-threatening tumours. PATIENTS AND
methods• From 1989 to 2001, we calculated two serial PSAV measurements in 18 214 prostate cancer screening-study participants, of whom 1125 (6.2%) were diagnosed with prostate cancer. • The PSAV risk count was determined as the number of PSAV measurements of >0.4 ng/mL/year (0, 1, or 2). • We used receiver operating characteristic (ROC) and reclassification analyses to examine the ability of PSAV risk count to predict screen-detected and high-grade prostate cancer.
results• The PSAV was >0.4 ng/mL/year twice (risk count 2) in 40% of prostate cancer cases compared with only 4% of those with no cancer (P < 0.001). • After adjusting for age and PSA level, a PSAV risk count of 2 was associated with an 8.2-fold increased risk of prostate cancer (95% confidence interval 7.0-9.6, P < 0.001) and 5.4-fold increased risk of Gleason score 8-10 prostate cancer on biopsy. • Compared with a model with age and PSA level, the addition of the PSAV risk count significantly improved discrimination (area under the ROC curve 0.625 vs 0.725, P= 0.031) and reclassified individuals for the risk of high-grade prostate cancer (net reclassification, P < 0.001).
conclusions• Sustained rises in PSA indicate a significantly greater risk of prostate cancer, particularly high-grade disease. • Compared with men with a risk count of ≤1, those with two PSAV measurements of >0.4 ng/mL/year (risk count 2) had an 8-fold increased risk of prostate cancer and 5.4-fold increased risk of Gleason 8-10 disease on biopsy, adjusting for age and PSA level. • Compared to PSA alone, PSAV risk count may be useful in reducing unnecessary biopsies and the diagnosis of low-risk prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.